Idenix gains $20M milestone

Cambridge, MA-based Idenix Pharmaceuticals has earned a hefty $20 million milestone based on ViiV Healthcare's progress with an experimental HIV/AIDS program. "We are pleased with the continued progress of '761 and the initiation of a Phase IIb clinical trial in HIV-infected patients," said Ronald Renaud, president and chief executive officer of Idenix. "We look forward to the continued progress of this program." Idenix release

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.